HC Wainwright reissued their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a $4.00 price target on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q4 2023 earnings at ($0.05) EPS, FY2023 earnings at […]
Related Keywords
, Atossa Therapeutics Company Profile , Northern Trust Corp , Atossa Therapeutics Inc , Sigma Securities , Charles Schwab Investment Management Inc , First Republic Investment Management Inc , Cantor Fitzgerald , Jpmorgan Chase Co , Atossa Therapeutics , Free Report , Get Free Report , Republic Investment Management , Trust Corp , Schwab Investment Management , Two Sigma Securities , Atossa Therapeutics Daily , Nasdaq Atos , Datos , Medical , Reiterated Rating , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.